- Home
- CGTX vs TPST Comparison
CGTX vs TPST Comparison
Compare CGTX & TPST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CGTX
- TPST
- Stock Information
- Founded
- CGTX 2007
- TPST 2011
- Country
- CGTX United States
- TPST United States
- Employees
- CGTX N/A
- TPST N/A
- Industry
- CGTX Biotechnology: Pharmaceutical Preparations
- TPST Biotechnology: Pharmaceutical Preparations
- Sector
- CGTX Health Care
- TPST Health Care
- Exchange
- CGTX Nasdaq
- TPST Nasdaq
- Market Cap
- CGTX 53.4M
- TPST 45.5M
- IPO Year
- CGTX 2021
- TPST N/A
- Fundamental
- Price
- CGTX $1.61
- TPST $10.04
- Analyst Decision
- CGTX Strong Buy
- TPST Hold
- Analyst Count
- CGTX 3
- TPST 3
- Target Price
- CGTX $2.83
- TPST $30.00
- AVG Volume (30 Days)
- CGTX 8.1M
- TPST 58.0K
- Earning Date
- CGTX 11-12-2025
- TPST 11-11-2025
- Dividend Yield
- CGTX N/A
- TPST N/A
- EPS Growth
- CGTX N/A
- TPST N/A
- EPS
- CGTX N/A
- TPST N/A
- Revenue
- CGTX N/A
- TPST N/A
- Revenue This Year
- CGTX N/A
- TPST N/A
- Revenue Next Year
- CGTX N/A
- TPST N/A
- P/E Ratio
- CGTX N/A
- TPST N/A
- Revenue Growth
- CGTX N/A
- TPST N/A
- 52 Week Low
- CGTX $0.22
- TPST $5.35
- 52 Week High
- CGTX $3.83
- TPST $20.67
- Technical
- Relative Strength Index (RSI)
- CGTX 42.22
- TPST 52.64
- Support Level
- CGTX $1.43
- TPST $9.90
- Resistance Level
- CGTX $2.60
- TPST $11.02
- Average True Range (ATR)
- CGTX 0.32
- TPST 0.63
- MACD
- CGTX -0.17
- TPST -0.16
- Stochastic Oscillator
- CGTX 10.81
- TPST 28.94
About CGTX Cognition Therapeutics Inc.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.
About TPST Tempest Therapeutics Inc.
Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets.